Annovis Bio Q2 2024 GAAP EPS $(0.44) Misses $(0.35) Estimate, Cash And Cash Equivalents Totaled $4M
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio reported a Q2 2024 GAAP EPS of $(0.44), missing the estimate of $(0.35). The company also reported cash and cash equivalents totaling $4 million.
August 15, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Annovis Bio reported a Q2 2024 GAAP EPS of $(0.44), missing the estimate of $(0.35). The company also reported cash and cash equivalents totaling $4 million.
The earnings miss is likely to negatively impact the stock price in the short term. Additionally, the relatively low cash and cash equivalents may raise concerns about the company's financial health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100